Picture loading failed.

Pre-Made Veltuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma. As of December 2011, it is undergoing Phase I/II clinical trials. When used with milatuzumab it showed activity.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-617-1mg 1mg 3090
GMP-Bios-ab-617-10mg 10mg Inquiry
GMP-Bios-ab-617-100mg 100mg Inquiry
GMP-Bios-ab-617-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Veltuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
INN Name Veltuzumab
TargetCD20
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2007
Year Recommended2008
CompaniesImmunomedics;Weill Cornell Medical College
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedChronic lymphocytic leukaemia;Rheumatoid arthritis;Idiopathic thrombocytopenic purpura;Non-Hodgkin's lymphoma;Follicular lymphoma
Development Techna